The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden

被引:16
|
作者
Jafarzadeh, Abdollah [1 ,2 ]
Kumar, Sunil [3 ]
Bodhale, Neelam [3 ]
Jafarzadeh, Sara [4 ]
Nemati, Maryam [2 ,5 ]
Sharifi, Iraj [6 ]
Sarkar, Arup [7 ]
Saha, Bhaskar [3 ,4 ,7 ]
机构
[1] Kerman Univ Med Sci, Sch Med, Dept Immunol, Kerman, Iran
[2] Rafsanjan Univ Med Sci, Res Inst Basic Med Sci, Mol Med Res Ctr, Rafsanjan, Iran
[3] Natl Ctr Cell Sci, Pune 411007, India
[4] Kerman Univ Med Sci, Student Res Comm, Sch Med, Kerman, Iran
[5] Kerman Univ Med Sci, Sch Para Med, Dept Haematol & Lab Sci, Kerman, Iran
[6] Kerman Univ Med Sci, Leishmaniasis Res Ctr, Kerman, Iran
[7] Trident Acad Creat Technol, Bhubaneswar, India
关键词
Leishmaniasis; Immune responses; Programmed death-1; PD-L1; PD-L2; T cell exhaustion; T-CELL EXHAUSTION; IFN-GAMMA; TGF-BETA; POSTTRANSLATIONAL MODIFICATIONS; VISCERAL LEISHMANIASIS; PROGRAMMED DEATH-1; IMMUNE-RESPONSE; DENDRITIC CELLS; RECEPTOR; CD8(+);
D O I
10.1016/j.cyto.2022.155839
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expression of programmed cell death protein-1 (PD-1) and its ligands-PD-L1 and PD -L2-on T cells and macrophages', respectively, increases in Leishmania infection. The PD-1/PD-L1 interaction induces T cell anergy, T cell apoptosis and exhaustion, diversion of T cells toward TH2 and T-reg cells but inhibits M1 macrophage activities by suppression of nitric oxide (NO) and reactive oxygen species (ROS) production. These changes exacerbate Leishmania infection. As PD-L1-deficient, but not PD-L2-deficient, mice were protected against L. mexicana infection, differential roles have been proposed for PD-L1 and PD-L2 in mouse models of leishmaniasis. Blockade of PD-1/PD-L1 interaction in various in vitro and Leishmania-infected mouse, hamster and dog models enhanced IFN-gamma and NO production, reduced IL-10 and TGF-8 generation, promoted T cell proliferation and reduced parasite burden. Therefore, PD-1/PD-L1 blockade is being considered as a potential therapeutic strategy to restore protective immunity during leishmaniasis, particularly, in drug-resistant cases.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] PD-1/PD-L1 expression and its implications in patients with chronic lymphocytic leukemia
    李金花
    ChinaMedicalAbstracts(InternalMedicine), 2017, 34 (02) : 120 - 121
  • [32] Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
    Calles, Antonio
    Liao, Xiaoyun
    Sholl, Lynette M.
    Rodig, Scott J.
    Freeman, Gordon J.
    Butaney, Mohit
    Lydon, Christine
    Dahlberg, Suzanne E.
    Hodi, F. Stephen
    Oxnard, Geoffrey R.
    Jackman, David M.
    Jaenne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1726 - 1735
  • [33] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Lipson, Evan J.
    Lilo, Mohammed T.
    Ogurtsova, Aleksandra
    Esandrio, Jessica
    Xu, Haiying
    Brothers, Patricia
    Schollenberger, Megan
    Sharfman, William H.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [34] Blockade of TNF receptor 1 reduces disease severity but increases parasite transmission during Plasmodium chabaudi chabaudi infection
    Long, Grainne H.
    Chan, Brian H. K.
    Allen, Judith E.
    Read, Andrew F.
    Graham, Andrea L.
    INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2008, 38 (8-9) : 1073 - 1081
  • [35] Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
    Ou, Huilin
    Chen, Keda
    Chen, Linfang
    Wu, Hongcheng
    BMC GENOMIC DATA, 2022, 23 (01):
  • [36] PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques
    Kauffman, Keith D.
    Sakai, Shunsuke
    Lora, Nickiana E.
    Namasivayam, Sivaranjani
    Baker, Paul J.
    Kamenyeva, Olena
    Foreman, Taylor W.
    Nelson, Christine E.
    Oliveira-de-Souza, Deivide
    Vinhaes, Caian L.
    Yaniv, Ziv
    Arleham, Cecilia S. Lindestam
    Sette, Alessandro
    Freeman, Gordon J.
    Moore, Rashida
    Sher, Alan
    Mayer-Barber, Katrin D.
    Andrade, Bruno B.
    Kabat, Juraj
    Via, Laura E.
    Barber, Daniel L.
    SCIENCE IMMUNOLOGY, 2021, 6 (55)
  • [37] Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
    Wang, Jie
    Fei, Keke
    Jing, Hua
    Wu, Zhihai
    Wu, Weiwei
    Zhou, Shuaixiang
    Ni, Haiqing
    Chen, Bingliang
    Xiong, Yan
    Liu, Yanpeng
    Peng, Bo
    Yu, Dechao
    Jiang, Haiping
    Liu, Junjian
    MABS, 2019, 11 (08) : 1443 - 1451
  • [38] Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
    Huilin Ou
    Keda Chen
    Linfang Chen
    Hongcheng Wu
    BMC Genomic Data, 23
  • [39] Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
    Zak, Krzysztof M.
    Grudnik, Przemyslaw
    Magiera, Katarzyna
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    STRUCTURE, 2017, 25 (08) : 1163 - 1174
  • [40] Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab
    Tavares, Ana Beatriz M. L. A.
    Lima Neto, J. X.
    Fulco, U. L.
    Albuquerque, E. L.
    PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2021, 23 (37) : 21207 - 21217